136 results
424B5
IFRX
InflaRx N.V.
28 Jun 24
Prospectus supplement for primary offering
4:56pm
, our anticipated financial performance and financial condition, and our business plans and growth strategy and product development efforts … for commercial use;
our manufacturing capabilities and strategy, including the scalability and cost of our manufacturing methods and processes
6-K
EX-99.1
IFRX
InflaRx N.V.
24 Jun 24
Current report (foreign)
4:16pm
of such protection; our manufacturing capabilities and strategy, including the scalability and cost of our manufacturing methods and processes
6-K
EX-99.1
IFRX
InflaRx N.V.
5 Jun 24
InflaRx Hosts R&D Event Highlighting the Promise of INF904
5:07pm
product candidates, and the scope of such protection; our manufacturing capabilities and strategy, including the scalability and cost of our manufacturing
6-K
EX-99.2
IFRX
InflaRx N.V.
5 Jun 24
InflaRx Hosts R&D Event Highlighting the Promise of INF904
5:07pm
property protection for vilobelimab and any other product candidates, and the scope of such protection; our manufacturing capabilities and strategy … IND submission. FPI scheduled for Q4 2024 with preliminary results expected in Summer 2025. Clinical development strategy
Phase 2a open label basket
6-K
EX-99.1
IFRX
InflaRx N.V.
21 May 24
Report of Foreign Private Issuer
4:15pm
, and the scope of such protection; our manufacturing capabilities and strategy, including the scalability and cost of our manufacturing methods
6-K
EX-99.2
q2ikxntg812gukx
8 May 24
Report of Foreign Private Issuer
8:43am
6-K
EX-99.3
nzi2mb h1t
8 May 24
Report of Foreign Private Issuer
8:43am
6-K
EX-99.1
s1w9pph9muy1puetuy
4 Apr 24
Current report (foreign)
4:01pm
6-K
EX-99.1
2e2jil8i
21 Mar 24
Corporate Presentation March 2024
5:00pm
6-K
EX-99.1
7h9rbakkit8et 6vt
21 Mar 24
InflaRx Reports Full Year 2023 Results and Announces INF904 Development Plans
7:05am
6-K
EX-99.1
po64 xf8zj
25 Jan 24
InflaRx Announces Initiation of its Commitment Program for GOHIBIC®(vilobelimab) to Help Broaden Access for Eligible Patients
8:00am
6-K
EX-99.1
tg85qo realftdp8rbi
4 Jan 24
InflaRx Announces Positive Topline Results from the Multiple Ascending Dose (MAD) Phase I Study with C5aR Inhibitor INF904
4:16pm
6-K
EX-99.2
fk1e2d2oj8
4 Jan 24
InflaRx Announces Positive Topline Results from the Multiple Ascending Dose (MAD) Phase I Study with C5aR Inhibitor INF904
4:16pm
6-K
EX-99.1
ga9d41rb k7gte
6 Nov 23
InflaRx Announces First Patient Dosed in Phase III Trial with Vilobelimab in Pyoderma Gangrenosum
8:00am
6-K
EX-99.2
cwf3bh9l
1 Nov 23
Current report (foreign)
8:04am
6-K
EX-99.3
bmqfbjl7i0iwa3a3yhw
1 Nov 23
Current report (foreign)
8:04am
6-K
EX-99.1
fsvlcvdqkt04txcc
11 Sep 23
InflaRx Announces Positive Topline Results from the Single Ascending Dose (SAD) Phase I Study with C5aR Inhibitor INF904
8:45am
6-K
EX-99.1
i57drqb9
30 Aug 23
Current report (foreign)
8:00am
6-K
EX-99.2
aen6vl1dn6n
10 Aug 23
Report of Foreign Private Issuer
8:00am